To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
The myelodysplastic syndromes (MDSs) are quite uncommon in children. Pediatric MDS is pathogenetically distinct from its adult counterpart and is characterized by a high frequency of germline mutations in GATA2, RUNX1, SAMD9, SAMD9L, and less frequently in genes encoding RAS signaling pathway components. The genomic landscape of pediatric MDS is distinct from that of adult cases and dominated by somatic driver mutations in SETBP1, RUNX1, ASXL1, and RAS pathway genes. A significant fraction of pediatric MDS cases develops in individuals with germline myeloid malignancy predisposition syndromes. These include the classic bone marrow failure syndromes (e.g., Fanconi anemia and Shwachman–Diamond syndrome), as well as several more recently described syndromes such as GATA2 deficiency or familial platelet disorder due to RUNX1 mutations. Three major types of pediatric MDSs are recognized in the International Consensus Classification, including refractory cytopenia of childhood, MDS with excess blasts, and MDS not otherwise specified. In this chapter, the molecular pathogenesis, histopathology, immunophenotypic findings of pediatric MDS are discussed in detail. Because several non-neoplastic disorders may pathologically mimic pediatric MDS, discussion of the differential diagnosis of MDS and the appropriate utilization of laboratory and molecular testing for accurate diagnosis is emphasized.
Acute myeloid leukemia (AML) is a group of clonal malignancies of the bone marrow and peripheral blood. Advances in our understanding of the genetic abnormalities responsible for the development of AML together with the rapidly evolving development of therapeutics that specifically target the underlying genetic lesions have necessitated further refinements in the classification of AML. This is reflected in the recently published International Consensus Classification of AML in which genetically based categorization of AMLs is incorporated to a greater extent than in previous World Health Organization classification schemes, with the goals of improving diagnostic precision, providing more meaningful prognostic information and identifying those patients for whom targeted therapeutics may be beneficial. Genetically defined AMLs account for a higher percentage of cases in children than in adults, and some AML subtypes occur solely in children. This chapter provides an overview of childhood AML, with an emphasis on those entities that are more common or restricted to the pediatric population. Discussion of each AML subtype includes a summary of the molecular pathogenesis and description of the relevant clinical, laboratory, pathologic, and molecular diagnostic features, with an emphasis on differential diagnosis and appropriate utilization of ancillary testing during the diagnostic workup of pediatric AML.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.